ArticleFrontiers in oncology2026
Case Report: KIF5B-ALK-rearranged renal cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (ALK-RCC) is a rare provisional entity characterized by fusion of the ALK gene with various fusion partner genes, resulting in oncogenic activation. Case presentation: We report a case of a 39-year-old Chinese man with ALK-RCC who underwent partial nephrectomy for a left renal tumor measuring 2.8 × 2.7× 2.6 cm. Histopathological examination revealed a renal epithelial tumor with atypical morphology. Immunohistochemistry demonstrated the occurrence of renal epithelial differentiation and excluded other entities. Next-generation sequencing confirmed a KIF5B-ALK gene fusion. Conclusion: This case presents the clinical data, morphology, immunohistochemistry, and molecular characteristics of a rare subtype of ALK-rearranged renal cell carcinoma with KIF5B-ALK fusion. The findings may enhance the clinical and pathological understanding of ALK-RCC among clinicians and pathologists. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene may have a role in patients with ALK-RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.